Premium
Helicobacter pylori infection in childhood: Results of management with ranitidine bismuth citrate plus amoxicillin and tinidazole
Author(s) -
Nijevitch Alexander A,
Farztdinov Karim M,
Sataev Valery U,
Khasanov Rinat Sh,
Katayev Valery A,
Khusnutdinov Shamil M,
Akhunov Eduard D,
Kazykhanov Nasghat S
Publication year - 2000
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1046/j.1440-1746.2000.2326.x
Subject(s) - medicine , gastroenterology , duodenitis , helicobacter pylori , amoxicillin , tinidazole , ranitidine , gastritis , clarithromycin , adverse effect , regimen , antibiotics , metronidazole , microbiology and biotechnology , biology
Background and Aims: To verify whether a triple therapy bismuth citrate plus amoxicillin and tinidazole eradicates H. pylori infection in pediatric patients. Methods: Fifty children (30 females; mean age 12.4 ± 1.1 years, range 10–15 years) suffering from upper abdominal complaints and Helicobacter pylori ( H. pylori )‐associated gastroduodenal disease were treated with a 4 week course of ranitidine bismuth citrate (400 mg, twice daily) plus oral tinidazole (20 mg/kg) and amoxicillin (50 mg/kg) for the first 2 weeks. Results: The endoscopic diagnoses were: esophagitis (seven cases), gastritis (six cases), gastroduodenitis (43 cases), duodenitis (one case), gastric ulcer (two cases) and duodenal ulcer (13 cases). Helicobacter pylori was eradicated in 40 (80%) patients and clinical improvement was noticed in 39 (78%) of symptomatic subjects. Duodenal ulcers were healed in all the children, but lymphoid nodular hyperplasia was persistent in all patients, independent of the H. pylori status. The potentially drug‐related adverse events (blackening of the tongue, six patients; diarrhea, one patient; disturbance of taste, two patients) were registered in seven (14%) patients and dark stools were observed in 48 (96%) patients. No children withdrew from the study because of either side‐effects or clinical laboratory changes. No patient had toxic levels of blood bismuth (values ranged between 2.1 and 5.4 μg/L, mean value 3.4 ± 1.04 μg/L). Conclusions: Findings suggest that the present treatment regimen is effective enough in the resolution of H. pylori ‐associated peptic ulcer disease of childhood.